

VOLUME 5 1976

UNIVERSITY OF HAWAII LIBRARY

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Editor-in-Chief

MATTHEW J. WAYNER

Published by

ANKHO International Inc

Phoenix, New York

Regional Editors

A. BARBEAU, Department of Neurobiology, Clinical Research Institute of Montreal, 110 West Pine Avenue, Montreal (130), Quebec, Canada

J. R. BOISSIER, Faculté de Médecine de Paris, Unité de Neuropsychopharmacologie, 2 rue d'Alésia, 75014 Paris, France

G. R. BREESE, Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514

E. A. CARLINI, Department of Psychobiology, Escola Paulista de Medicina, Rua Botucatu, 862, 04023 - São Paulo, Brasil

J. COCHIN, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, 80 East Concord Street, Boston, Massachusetts 02118

D. V. COSCINA, Section of Neurochemistry, Clarke Institute of Psychiatry, 250 College Street, Toronto, Ontario M5T 1R8, Canada

G. ELLMAN, Langley Porter Institute, San Francisco, California 94122

K. ERIKSSON, Research Laboratories of State Alcohol Monopoly, Box 350, 00101 Helsinki 10, Finland

J. L. FALK, Department of Psychology, Rutgers University, New Brunswick, New Jersey 08903

E. GELLER, Neurobiochemistry Laboratory, T-85 Veterans Administration, Brentwood Hospital, Los Angeles, California 90073

S. P. GROSSMAN, Department of Psychology, University of Chicago, Chicago, Illinois 60637

Y. GUTMAN, Department of Pharmacology, The Hebrew University, Hadassah Medical School, P.O. Box 1172, Jerusalem, Israel

G. H. HALL, Department of Pharmacology, School of Pharmacy, Sunderland Polytechnic, Sunderland, SR1 3SD, Co. Durham, England

J. HANO, Polish Academy of Sciences, Institute of Pharmacology, 52, Ojcowska Street, 31 344 Krakow, Poland

J. A. HARVEY, Department of Psychology, University of Iowa, Iowa City, Iowa 52240

P. JANSSEN, Research Laboratoria, Janssen Pharmaceutica, 2340-Beerse, Belgium

D. A. KHARKEVICH, Department of Pharmacology, First Medical Institute, 2/6, Bolshaja Pirogovskaja Street, Moscow, G-435, USSR

J. KNOLL, Department of Pharmacology, Semmelweis University of Medicine, Budapest VIII, Üllői út 26, Hungary

I. P. LAPIN, Laboratory of Psychopharmacology, Bekhterev Institute, Bekhtereva ul., 3, 193019 Leningrad, USSR

A. E. LEBLANC, Biological Studies Research Division, Alcoholism and Drug Addiction Research Foundation, 33 Russell Street, Toronto, Ontario M5S 2S1, Canada

V. G. LONGO, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Roma, Italy

H. MATTHIES, Institut für Pharmakologie und Toxikologie, Medizinische Akademie Magdeburg, 301 Magdeburg, Leipziger Strasse 44, German Democratic Republic

N. K. MELLO, Alcohol and Drug Abuse Research Center, Harvard Medical School, McLean Hospital, Belmont, Massachusetts 02178.

R. D. MYERS, Laboratory of Neuropsychology, Purdue University, Lafayette, Indiana 47907

R. H. RECH, Department of Pharmacology, Michigan State University, B440 Life Sciences, East Lansing, Michigan 48824

J. A. ROSECRANS, Department of Pharmacology, Virginia Commonwealth University, Medical College of Virginia, Health Sciences Center, Richmond, Virginia 23219

C. R. SCHUSTER, Department of Psychiatry, University of Chicago, 950 East 59th Street, Chicago, Illinois 60637

D. S. SEGAL, Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, California 92037

L. S. SEIDEN, Department of Pharmacology, University of Chicago, Chicago, Illinois 60637

E. B. SIGG, Department of Neuropharmacology, Research Division, Hoffman-La Roche Inc., Nutley, New Jersey 07110

G. SINGER, Department of Psychology, La Trobe University, Bundoora, Victoria 3083, Australia

T. L. SOURKES, Allan Memorial Institute of Psychiatry, 1025 Pine Avenue West, Montreal 112, P. Q., Canada

P. STERN, Department of Pharmacology, Medical Faculty, Moše Pijade 6, Sarajevo 71001, Yugoslavia

W. C. STERN, Medical Division, Burroughs Wellcome Co., 3030 Cornwallis Road, Research Triangle Park, NC 27709

S. TADOKORO, Behavior Research Institute, School of Medicine, Gunma University, 3-39-22, Showamachi Maebashi 371, Japan

T. THOMPSON, Department of Psychiatry, University of Minnesota, Research Unit, Medical School, Box 392, Mayo Memorial Building, Minneapolis, Minnesota 55455

U. UNGERSTEDT, Department of Histology, Karolinska Institutet, Solnavägen 1, S-104 01 Stockholm 60, Sweden

W. L. VEALE, Division of Medical Physiology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada

J. E. VILLARREAL, Department of Behavioral Pharmacology, Instituto Miles de Terepente Experimental, Division de Laboratorios Miles de Mexico, S.A. de C.V., Apartado Postal 22026, Mexico 22, D.F.

Z. VOTAVA, Department of Pharmacology, Research Institute of Pharmacy and Biochemistry, Praha 3, Kourimská 17, Czechoslovakia

W. WUTTKE, Institut für Pharmakologie, Farbenfabriken Bayer AG, 56 Wuppertal-Elberfeld, Friederich-Ebert-Strasse 217, Germany

T. YANAGITA, Central Institute for Experimental Animals, 1433 Nogawa, Kawasaki 211, Japan

Editorial Advisory Board

B. AGRANOFF (*Ann Arbor*)

B. BEER (*Princeton*)

M. H. APRISON (*Indianapolis*)

E. F. DOMINO (*Ann Arbor*)

D. X. FREEDMAN (*Chicago*)

E. GLASSMAN (*Chapel Hill, N.C.*)

H. KALANT (*Toronto*)

A. J. MANDELL (*San Diego*)

J. MENDELSON (*Boston*)

S. H. SNYDER (*Baltimore*)

E. USDIN (*Rockville, Md.*)

R. J. WURTMAN (*Cambridge, Mass.*)

Subscription, postpaid: \$160 per year for Libraries, Research Establishments and all other multiple-reader Institutions.

Private individuals whose departmental libraries subscribe may obtain this Journal for their personal use at a reduced rate of \$25.00 per year.

Subscription Office: ANKHO International Inc.

P.O. Box 65, Phoenix, New York 13135 U.S.A.

Back issues are available. Write for Back Issues Price List.

Published monthly. Copyright © 1976 ANKHO International Inc.

Publishing and Advertising Offices:

ANKHO International Inc.

7374 Highbridge Terrace, P.O. Box 426, Fayetteville, New York 13066 U.S.A.

Application to mail at second-class postage rates is pending at Fayetteville, New York 13066.

CONTENTS

The effect of memory blocking antibiotics and their analogs on acetylcholinesterase. SPRINGER, A. D., J. SCHACHT and B. W. AGRANOFF	1
The drinking response of the chicken to peripheral and central administration of angiotensin II. SNAPIR, N., B. ROBINZON and M. GODSCHALK	5
Effects of intracisternal GABA or glutamic acid upon behavioral activity in the rat. FREED, W. J. and E. MICHAELIS	11
Papaverine, drug-induced stereotypy and catalepsy and biogenic amines in the brain of the rat. KOSTOWSKI, W., S. GAJEWSKA, A. BIDZINSKI and M. HAUPTMAN	15
The effect of 6-aminodopamine on electrical self-stimulation in rats. MONASMITH, B., P. PLOTSKY, C. L. BLANK and R. N. ADAMS	19
Spontaneous and amphetamine induced head-shaking in infant rats. HOLMGREN, B., R. URBÁ-HOLMGREN and M. VALDÉS	23
Relative role of catecholamines in head-shaking of infant rats. HOLMGREN, B., R. URBÁ-HOLMGREN and M. VALDÉS	29
Alterations in the behavioral effects of LSD by motivational and neurohumoral variables. JOSEPH, J. A. and J. B. APPEL	35
Short-term memory in the rhesus monkey: disruption from the anti-cholinergic scopolamine. BARTUS, R. T. and H. R. JOHNSON	39
Effects of rapid depletion of phenylalanine and tyrosine on sleep and behavior. BARRATT, E. S., P. M. ADAMS, P. L. POFFENBARGER, R. R. FRITZ and C. W. ABELL	47
The role of serotonergic pathways in isolation-induced aggression in mice. MALICK, J. B. and A. BARNETT	55
Genetic differences in ethanol drinking of the rat following injection of 6-OHDA, 5,6-DHT or 5,7-DHT into the cerebral ventricles. MELCHIOR, C. L. and R. D. MYERS	63
Cortical administration of somatostatin (SRIF): effect on sleep and motor behavior. REZEK, M., V. HAVLICEK, K. R. HUGHES and H. FRIESEN	73
Hypothermia induced by Δ^9 -tetrahydrocannabinol in rats with electrolytic lesions of the preoptic region. SCHMELING, W. T. and M. J. HOSKO	79

BRIEF COMMUNICATIONS

Impairment of Hebb-Williams maze performance following prolonged alcohol consumption in rats. BOND, N. W. and E. L. DI GIUSTO	85
Behavioral depression: thyroid interactions with norepinephrine-depleting drugs. DAVENPORT, J. W., R. S. HENNIES, J. C. CAREY and S. B. BISHOP	87

ANNOUNCEMENTS

12–15 October, 1976, New York City. New York Academy of Sciences conference on Evolution and Lateralization of the Brain	91
30 March–1 April, 1977, New York City. New York Academy of Sciences conference on Serotonin Neurotoxins	92
New Publication. <i>Developmental Neurobiology</i>	93

CONTENTS

Dose-dependent dual effect of morphine on electrophysiologic correlates of positive reinforcement (Reward Contingent Positive Variation: RCPV) in the cat. MARCZYNSKI, T. J. and J. T. HACKETT	95
Abolition of nomifensine-induced stereotypy after 6-hydroxydopamine lesions of ascending dopaminergic projections. PRICE, M. T. C. and H. C. FIBIGER	107
Effects of handling and etherization on incorporation of [³ H] lysine into protein of mouse brain and liver. ENTINGH, D. J. and T. DAMSTRA	111
Effect of two inhibitors of dopamine β -hydroxylase on maturation of memory in mice. FLEXNER, J. B. and L. B. FLEXNER	117
The role of reinforcement loss in tolerance to chronic Δ -9-tetrahydrocannabinol effects on operant behavior of rhesus monkeys. ELSMORE, T. F.	123
Neurochemical and behavioral effects of diet related perinatal folic acid restriction. MIDDAGH, L. D., T. A. GROVER, L. A. BLACKWELL and J. W. ZEMP	129
The effect of alpha and beta adrenergic receptor blockers on sleep in the rat. HARTMANN, E. and G. ZWILLING	135
Effects of diazepam and ripazepam on two measures of adjunctive drinking in rats. SANGER, D. J. and D. E. BLACKMAN	139
Lithium levels in monkey and human brain after chronic, therapeutic, oral dosage. SPIRITES, M. A.	143
Amphetamine, chlorpromazine and clonidine effects on self-stimulation in caudate or hypothalamus of the squirrel monkey. SPENCER, J. and A. REVZIN	149
Scopolamine: effects on fear or defense response in the rat. MOLLENAUER, S., R. PLOTNIK and P. SOUTHWICK	157
Neurohumoral correlates of sleep: further biochemical and physiological characterization of sleep perfusates. SPANIS, C. W., M. DEL CARMEN GUTIÉRREZ and R. R. DRUCKER-COLÍN	165
Dyskinesias in monkeys: interaction of methamphetamine with prior methadone treatment. EIBERGEN, R. D. and K. R. CARLSON	175
Enhancement of the locomotor response to d-amphetamine by olfactory bulb damage in rats. GADDY, J. R. and D. B. NEILL	189
Interactions between naloxone and narcotic analgesics under three schedules that induce polydipsia. MCMILLAN, D. E. and J. D. LEANDER	195
On the anticataleptic action of cyproheptadine. MAJ, J., J. SARNEK, V. KLIMEK and A. RAWLÓW	201
Intracranial injections of 6-OHDA: comparison of catecholamine-depleting effects of different volumes and concentrations. WILLIS, G. L., G. SINGER and B. K. EVANS	207

- A dose-response study of anorectic drug effects on food intake, self-stimulation, and stimulation-escape. KORNBLITH, C. L. and B. G. HOEBEL 215

BRIEF COMMUNICATIONS

- Comparison of α -MSH and several vasoactive substances on vascular resistance in the feline mesenteric vascular bed. KADOWITZ, P. J., B. M. CHAPNICK and A. J. KASTIN 219
- Acute and chronic single dose effects of LSD-25 on visual discrimination in rats. FRIEDMAN, H. and R. J. CAREY 223
- Response suppression on a mixed schedule of reinforcement during alcohol withdrawal in rats. DENOBLE, V. J. and H. BEGLEITER 227

ANNOUNCEMENTS

- 12–15 October, 1976, New York City. New York Academy of Sciences conference on Evolution and Lateralization of the Brain 231
- 30 March–1 April, 1977, New York City. New York Academy of Sciences conference on Serotonin Neurotoxins 232
- 27 April–1 May, 1977, Houston, Texas. Association for the Psychophysical Study of Sleep (APSS), 17th Annual Meeting 233
- New Publication. *Developmental Neurobiology* 234

CONTENTS

Effects of nicotinic and muscarinic compounds on biting attack in the cat. BERNTSON, G. G., M. S. BEATTIE and J. M. WALKER	235
Effect of serotonergic drugs on positive and negative reinforcing systems in cats. PATKINA, N. A. and I. P. LAPIN	241
Effect of catecholaminergic drugs on systems of reward and punishment in experiments on cats. PATKINA, N. A. and I. P. LAPIN	247
Evoked potential alterations in methylmercury chloride toxicity. ZENICK, H.	253
Effects of carbon monoxide on fixed-consecutive-number performance in rats. SMITH, M. D., W. H. MERIGAN and R. W. MCINTIRE	257
Butanediols: selection, open field activity and NAD reduction by liver extracts in inbred mouse strains. GOLDBORT, R., C. W. SCHNEIDER and R. A. HARTLINE	263
Role of experience in acquisition and loss of tolerance to the effect of Δ -9-THC on spaced responding. MANNING, F. J.	269
Intraventricular anti-cholinergics do not block cholinergic hippocampal RSA or neocortical desynchronization in the rabbit or rat. WHISHAW, I. Q., T. E. ROBINSON AND T. SCHALLERT	275
Interaction of d-amphetamine with pentobarbital and chlordiazepoxide: effects on punished and unpunished behavior of pigeons. BARRETT, J. E. and J. M. WITKIN	285
Dissociation of the effects of scopolamine and d-amphetamine on a spontaneous alternation task. KOKKINIDIS, L. and H. ANISMAN	293
Triethyltin toxicity as a model for degenerative disorders. GERREN, R. A., D. E. GROSWALD and M. W. LUTTGES	299
Effects of intracranial injections of 6-OHDA on food and water intakes, body temperature and body weight regulation in the rat. SINGER, G. and S. ARMSTRONG	309
Sexual behavior in castrated male rats treated with monoamine synthesis inhibitors and testosterone. SÖDERSTEN, P., K. LARSSON, S. AHLENIUS and J. ENGEL	319
Stimulation of mounting behavior but not lordosis behavior in ovariectomized rats by p-chlorophenylalanine. SÖDERSTEN, P., K. LARSSON, S. AHLENIUS and J. ENGEL	329
Ethanol elimination rates in normal and ethanol dependent animals. SAMSON, H. H., D. C. MORGAN, C. M. PRICE, M. TANG and J. L. FALK	335
The effects of acute and chronic administration of caffeine on schedule dependent and schedule induced behavior. WAYNER, M. J., F. B. JOLICOEUR, D. B. RONDEAU and F. C. BARONE	343
Enhancement of effects of dopaminergic agonists on neuronal activity in the caudate-putamen of the rat following long-term d-amphetamine administration. REBEC, G. V. and P. M. GROVES	349

BRIEF COMMUNICATIONS

- Plug-holder unit for implanting stimulating and recording electrodes. CLANCY, J. J., D. F. CALDWELL and J. M. SZOPO 359
- Simple flow-thru swivel for infusions into unrestrained animals. BROWN, Z. W., Z. AMIT and J. R. WEEKS 363
- Effects of methadone on activity and on brain monoamines in two strains of mice. MIDDAUGH, L. D. and J. W. ZEMP 367
- The role of hippocampal cholinergic mechanisms in the acquisition of a barpress response. JAFFARD, R., A. EBEL, C. DESTRADE, G. AYAD, P. MANDEL and B. CARDO 371

ANNOUNCEMENTS

- 30 March—1 April, 1977, New York City. New York Academy of Sciences conference on Serotonin Neurotoxins 375
- 27 April—1 May, 1977, Houston, Texas. Association for the Psychophysical Study of Sleep (APSS), 17th Annual Meeting 376
- 5—8 June, 1977, Magdeburg, D.D.R. V International Neurobiological Symposium 377
- New Publication. *Developmental Neurobiology* 378
- Supplement to *Pharmac. Biochem. Behav.*, Volume 5, 1976. *The Neuropeptides* 379

CONTENTS

Locomotor activity and plasma, red blood cell and cerebral cortex lithium concentration in inbred mice given lithium carbonate. SMITH, D. F.	379
The tryptolines: effect of intraventricular administration on spontaneous motor activity of rats. GREEN, R. A., J. D. BARCHAS, G. R. ELLIOTT, J. S. CARMAN and R. J. WYATT	383
Effect of tetraethyl lead on food and water intake in the rat. CZECH, D. A., J. C. SCHMIDT and J. M. STONE	387
Effects of para-chlorophenylalanine upon brain stimulated affective attack in the cat. KATZ, R. J. and E. THOMAS	391
Secondary reinforcement property of a stimulus paired with morphine administration in the rat. NUMAN, R., U. BANERJEE, N. SMITH and H. LAL	395
Discriminative stimulus properties of fentanyl and morphine: tolerance and dependence. COLPAERT, F. C., J. J. M. D. KUYPS, C. J. E. NIEMEGEERS and P. A. J. JANSSEN	401
Ethanol and delta-9-tetrahydrocannabinol: mechanism for cross-tolerance in mice. SPRAGUE, G. L. and A. L. CRAIGMILL	409
Chronic intermittent ethyl alcohol inhalation and avoidance learning. SOTZING, J. H. and T. S. BROWN	417
Metrazol potentiated after-discharges: dose-response relationships and effects of selective lesions. BIGLER, E. D., D. E. FLEMING and D. E. SHEARER	423
Noradrenaline synthesis from L-DOPA in rodents and its relationship to motor activity. DOLPHIN, A., P. JENNER and C. D. MARSDEN	431
Isolation and identification of two learning-induced brain peptides. TATE, D. F., L. GALVAN and G. UNGAR	441
Development of cholinergic inhibitory capacities in the hyperthyroid mouse. MURPHY, J. M. and Z. M. NAGY	449
Monoaminergic mediation of masculine and feminine copulatory behavior in female rats. RODRIGUEZ-SIERRA, J. F., A. N. NAGGAR and B. R. KOMISARUK	457
Effects of lesions of the caudate nucleus on morphine dependence in the rat. LINSEMAN, M. A.	465
Effect of subcutaneous vs intraperitoneal administration of an anti-estrogen, CI-628 on estradiol- and estradiol benzoate-stimulated lordosis in the ovariectomized rat. LANDAU, I. T.	473
Role of noradrenergic and dopaminergic processes in amphetamine self-administration. RISNER, M. E. and B. E. JONES	477

THEORETICAL REVIEW

Schedule induced behavior: a review of its generality, determinants and pharmacological data. WALLACE, M. and G. SINGER	483
---	-----

BRIEF COMMUNICATIONS

- Noradrenergic feeding system in monkey hypothalamus is altered by localized perfusion of glucose, insulin, 2-DG and eating. MCQUEEN, A., S. ARMSTRONG, G. SINGER and R. D. MYERS 491
- Stimulation of food intake in horses by diazepam and promazine. BROWN, R. F., K. A. HOUPPT and H. F. SCHRYVER 495
- DDC-induced retrograde amnesias prevented by injections of dl-DOPS. HAMBURG, M. D. and A. KERR 499

ANNOUNCEMENT

- Brain Information Service publication: *Memory and Learning – Research in the Nervous System* 503

CONTENTS

Effects of d- and l-amphetamine on dorsal and ventral hypothalamic self-stimulation in three inbred strains of mice. CAZALA, P.	505
Acute functional tolerance to the motor impairment effects of di-n-propylacetate. KULIG, B. M. .	511
Effects of alpha methyltyrosine and parachlorophenylalanine on open field behavior in rats given tranlycypromine stereoisomers and lithium carbonate. SMITH, D. F. and M. SHIMIZU	515
Effects of selective forebrain depletions of norepinephrine and serotonin on the activity and food intake effects of amphetamine and fenfluramine. CAREY, R. J.	519
Facilitation of retention performance in mice by posttraining diethyldithiocarbamate. HAYCOCK, J. W., R. VAN BUSKIRK and J. L. MCGAUGH	525
Effect of magnesium deficiency on nonspecific excitability level (NEL) and audiogenic seizure susceptibility. BUCK, D. R., A. W. MAHONEY and D. G. HENDRICKS	529
Effects of pentobarbital on punished behavior at different shock intensities. WITKIN, J. M. and J. E. BARRETT	535
Effect of ACTH 4-10 on copulatory behavior and on the response in a test for socio-sexual motivation in the female rat. MEYERSON, B. J. and B. BOHUS	539
Effects of lithium chloride on sleep patterns in the rat. DANGUIR, J., S. NICOLAIDIS and M.-C. PERINO-MARTEL	547
Effects of monosodium glutamate on somatic development, obesity and activity in the mouse. PIZZI, W. J. and J. E. BARNHART	551
Brain 5-hydroxytryptamine correlates of behavior: studies involving spontaneously hypertensive (SHR) and normotensive Wistar rats. ROSECRANS, J. A. and M. D. ADAMS	559
Abnormal open field behavior after anterolateral hypothalamic injection of 6-hydroxydopamine. YOUNG, R. C., G. N. ERVIN and G. P. SMITH	565
Biochemical actions of sympathomimetic drugs which overcome cycloheximide-induced amnesia. JEFFREY, P. L. and M. E. GIBBS	571
Variable interval responding maintained by intravenous codeine and ethanol injections in the rhesus monkey. CARNEY, J. M., M. E. LLEWELLYN and J. H. WOODS	577

BRIEF COMMUNICATIONS

The discriminability of aspirin in arthritic and nonarthritic rats. WEISSMAN, A.	583
Behavioral, biochemical and histological effects of prenatal administration of progesterone in the rat. COYLE, I. R., R. ANKER and B. CRAGG	587
Carbachol, angiotensin-II, ventricular spread and water balance in rats. PECK, J. W.	591

CONTENTS

Effects of imipramine, chlorimipramine, and fluoxetine on cataplexy in dogs. BABCOCK, D. A., E. L. NARVER, W. C. DEMENT and M. M. MITLER	599
A comparison of withdrawal in rats implanted with different types of morphine pellets. MEYER, D. R. and S. B. SPARBER	603
Involvement of the medial hypothalamus and the septal area in the control of food intake and body weight in geese. SNAPIR, N., M. YAAKOBI, B. ROBINZON, H. RAVONA and M. PEREK	609
Effects of food restriction and mutation on central catecholamine levels in genetically obese mice. OLTMANS, G. A., J. F. LORDEN and D. L. MARGULES	617
Actions of repeated injections of LSD and apomorphine on the copulatory response of female rats. ELIASSON, M.	621
Differentiation of neuropharmacological actions of apomorphine and d-amphetamine. QUOCK, R. M. and A. HORITA	627
Drinking induced by parenteral injections of pilocarpine. GAY, P. E., S. C. BENNER and R. C. LEAF	633
Marijuana and memory impairment: the effect of retrieval cues on free recall. MILLER, L., T. CORNETT, D. BRIGHTWELL, D. MCFARLAND, W. G. DREW and A. WIKLER	639
Does tolerance develop to low doses of d- and l-amphetamine on locomotor activity in rats? WESTON, P. F. and D. H. OVERSTREET	645
Phencyclidine-induced rotational behavior in rats with nigrostriatal lesions and its modulation by dopaminergic and cholinergic agents. FINNEGAN, K. T., M. I. KANNER and H. Y. MELTZER	651
Effect of β -phenylethylamine and d-amphetamine on electrical self-stimulation of brain. HOWARD, J. L., G. T. POLLARD, K. W. ROHRBACH and N. E. HARTO	661
Antagonism of isolation-induced aggression in mice by thyrotropin-releasing hormone (TRH). MALICK, J. B.	665
Blockade of apomorphine's discriminative stimulus properties: relation to neuroleptic activity in neuropharmacological and biochemical assays. COLPAERT, F. C., J. E. M. F. LEYSEN, C. J. E. NIEMEGEERS and P. A. J. JANSSEN	671
Effects of response requirement upon human sedative self-administration and drug-seeking behavior. BIGELOW, G. E., R. R. GRIFFITHS and I. A. LIEBSON	681
Diminished reaction to a novel stimulus during amphetamine withdrawal in rats. SCHREIBER, H., R. BELL, L. CONELY, M. KUFNER, J. PALET and L. WRIGHT	687
Enkephalin and a potent analog facilitate maze performance after intraperitoneal administration in rats. KASTIN, A. J., E. L. SCOLLAN, M. G. KING, A. V. SCHALLY and D. H. COY	691

BRIEF COMMUNICATIONS

- Evidence that the preoptic region is a receptive site for the dipsogenic effects of angiotensin II.
ASSAF, S. Y. and G. J. MOGENSON 697
- Cocaine and morphine self-administration: effects of differential rearing. HILL, S. Y. and B. J.
POWELL 701
- Differences in cytochrome P-450 of various strains of rats following chronic administration of
pentobarbital. CREEL, D., D. E. SHEARER and P. F. HALL 705
- Inhibitory effect of midbrain raphe stimulation on the maintenance of an active avoidance reflex.
KOVÁCS, G. L. and G. TELEGDY 709
- The influence of hypothalamic temperature on some thermoregulatory effects of hypothalamic
injections of norepinephrine. LAUDENSLAGER, M. L. 713

ANNOUNCEMENT

- 8–12 May, 1977, Atlanta, Georgia. Eighth International Congress of the International Society of
Psychoneuroendocrinology 719

THE NEUROPEPTIDES

Pharmacology, Physiological Substrates and Behavioral Effects

Supplement to *PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR*

CONTENTS

Introduction. SANDMAN, C. A., L. H. MILLER and A. J. KASTIN	1
---	---

ATTENTION

Effects of neonatal cerebral ventricular injection of ACTH 4-9 and subsequent adult injections on learning in male and female albino rats. CHAMPNEY, T. F., T. L. SAHLEY and C. A. SANDMAN	3
Influence of three short-chain peptides (α -MSH, MSH/ACTH 4-10, MIF-I) on dimensional attention. BECKWITH, B. E., C. A. SANDMAN and A. J. KASTIN	11
Neuroheptapeptide influence on attention and memory in man. MILLER, L. H., L. C. HARRIS, H. VAN RIEZEN and A. J. KASTIN	17
Neuropeptide MSH/ACTH 4-10 enhances attention in the mentally retarded. SANDMAN, C. A., J. GEORGE, B. WALKER, J. D. NOLAN and A. J. KASTIN	23

LEARNING AND MEMORY

Dorsal hippocampus: a site of action of neuropeptides on avoidance behavior? WIMERSMA GREIDANUS, T.J.B. VAN and D. DE WIED	29
Does the rat with hereditary hypothalamic diabetes insipidus have impaired avoidance learning and/or performance? MILLER, M., E. G. BARRANDA, M. C. DEAN and F. R. BRUSH	35
Effects of ACTH peptide fragments on memory formation. FLOOD, J. F., M. E. JARVIK, E. L. BENNETT and A. E. ORME	41
Reversal of amnesia by an orally active ACTH 4-9 analog (Org 2766). RIGTER, H., R. JANSSENS-ELBERTSE and H. VAN RIEZEN	53
Effects of α -MSH on motivation, vigilance and brain respiration. PANKSEPP, J., P. REILLY, P. BISHOP, R. B. MEEKER, T. R. VILBERG and A. J. KASTIN	59
Neonatal treatment with TRH affects development, learning, and emotionality in the rat. STRATTON, L. O., C. A. GIBSON, K. G. KOLAR and A. J. KASTIN	65
ACTH 4-10 and short-term memory. DORNBUSH, R. L. and O. NIKOLOVSKI	69
Cognitive effects of ACTH 4-10 in the elderly. FERRIS, S. H., G. SATHANANTHAN, S. GERSHON, C. CLARK and J. MOSHINSKY	73

EMOTIONS AND SOCIAL BEHAVIOR

MIF, TRH and simian social and motor behavior. CROWLEY, T. J. and M. HYDINGER	79
Clinical investigations for emotional effects of neuropeptide hormones. EHRENSING, R. H. and A. J. KASTIN	89
Pituitary responses to thyrotropin releasing hormone in depressed patients: a review. LOOSEN, P. T., A. J. PRANGE, JR., I. C. WILSON and P. P. LARA	95

PHARMACOLOGY

- Effects of angiotensin on drinking. WAYNER, M. J., A. D. MERKEL, F. C. BARONE, F. B. JOLICOEUR and D. B. RONDEAU 103
- Effects of TRH on the central nervous system of the rabbit. HORITA, A., M. A. CARINO and J. R. SMITH 111
- Investigations on α -MSH and MIF-I effects on cyclic AMP levels in rat brain. CHRISTENSEN, C. W., C. T. HARSTON, A. J. KASTIN, R. M. KOSTRZEWA and M. A. SPIRTEs 117
- Possible association of increased rat behavior effects and increased striatal dopamine and norepinephrine levels during the DOPA-potential test. SPIRTEs, M. A., N. P. PLOTNIKOFF, R. M. KOSTRZEWA, C. T. HARSTON, A. J. KASTIN and C. W. CHRISTENSEN 121
- Effects of L-prolyl-L-leucyl-glycine amide (MIF-I) on dopaminergic neurons. KOSTRZEWA, R. M., M. A. SPIRTEs, JOAN W. KLARA, C. W. CHRISTENSEN, A. J. KASTIN and T. H. JOH 125
- Regulation of behavioral events by thyrotropin releasing factor and cyclic AMP. COHN, M. L., M. COHN, B. A. KRZYSIK and F. H. TAYLOR 129
- Comparison of the analeptic potency of TRH, ACTH 4-10, LHRH, and related peptides. BISSETTE, G., C. B. NEMEROFF, P. T. LOOSEN, A. J. PRANGE JR. and M. A. LIPTON .. 135
- Neurochemical responses of mice to ACTH and lysine vasopressin. DUNN, A. J., P. M. IUVONE and H. D. REES 139
- An endogeneous inhibitor of N-methyltransferase activity and opiate receptor binding in rabbit tissue. ROSENGARTEN, H., G. MARZULLO and A. J. FRIEDHOFF 147
- Peptides readily penetrate the blood-brain barrier: uptake of peptides by synaptosomes is passive. GREENBERG, R., C. E. WHALLEY, F. JOURDIKIAN, I. S. MENDELSON, R. WALTER, K. NIKOLICS, D. H. COY, A. V. SCHALLY and A. J. KASTIN 151

SUBSTRATES OF NEUROPEPTIDE ACTIVITY

- Neurologically active peptides. BARBEAU, A., M. GONCE and A. J. KASTIN 159
- Hormones and regional brain blood flow. GOLDMAN, H., E. B. SKELLEY, C. A. SANDMAN, A. J. KASTIN and S. MURPHY 165
- Hypothalamic releasing factors: physiological evidence for a regulatory action on central neurons and pathways for their distribution in brain. RENAUD, L. P., J. B. MARTIN and P. BRAZEAU 171
- Peptide enhancement of neuromuscular function: animal and clinical studies. STRAND, F. L., A. CAYER, E. GONZALEZ and H. STOBOY 179
- Author Index 189
- Subject Index 191

Pharmacology Biochemistry & Behavior will publish original reports of systematic studies in the areas of pharmacology, biochemistry, toxicology and behavior in which the primary emphasis and theoretical context are behavioral; and brief communications which describe a new method, technique or apparatus and results of experiments which can be reported briefly with limited figures

and tables. Behavioral studies as such will not be published unless they are obviously pertinent and make a significant contribution to pharmacology, biochemistry or toxicology. A limited number of relevant reviews and theoretical articles, results of symposia, and more comprehensive studies as monograph supplements will also be published. Articles will be published in English.

The accepted abbreviation for *Pharmacology Biochemistry & Behavior* for bibliographic citation is *Pharmac. Biochem. Behav.*

INSTRUCTIONS TO AUTHORS

Manuscripts should be sent directly to the Editor-in-Chief or to the most proximal Regional Editor for review and will be published within three months or less after formal acceptance.

STYLE OF MANUSCRIPT

General Form. (1) Manuscripts should be submitted in duplicate and should be typewritten, double spaced with wide margins on good quality paper. (2) The title page should contain: title of paper; author(s); laboratory or institution of origin with city, state, zip code, and country; complete address for mailing proofs; a running head not to exceed 50 characters including spaces between words. (3) References, footnotes, and legends for illustrations should be typed on separate sheets, double spaced. (4) Illustrations (unmounted photographs) should be identified on the reverse with figure number and author(s) name; when necessary the top should be clearly marked. (5) Each table should be typed on a separate sheet and double spaced. (6) All dimensions and measurements must be specified in the metric system. Standard nomenclature, abbreviations and symbols, as specified by Royal Society Conference of Editors. Metrication in Scientific Journals, *Am. Scient.* 56: 159-164, 1968, should be used throughout. (7) Italics should not be used for the purpose of emphasis.

Title. The title should not be longer than 85 characters, including spaces between words.

Papers in a series such as: "Studies on . . . I." will not be accepted.

Length of Paper. The Editors insist upon clear, concise statement of facts and conclusions. Fragmentation of material into numerous short reports is discouraged.

Abstract. Each paper submitted must be accompanied by an abstract, which does not exceed 170 words and must be suitable for use by abstracting journals. Abstracts should be prepared as follows:

EVANS, B. K., S. ARMSTRONG, G. SINGER, R. D. COOK AND G. BURNSTOCK. *Intracranial injection of drugs: comparison of diffusion of . . . PHARMAC. BIOCHEM. BEHAV.* Marked differences in extent of diffusion have been . . .

A list of from 3-12 (or more) words or short phrases suitable for indexing terms should be typed at the bottom of the abstract page accompanying the manuscript. These terms will be printed with the paper at the end of the abstract.

Drugs. Proprietary (trademarked) names should be capitalized. The chemical name should precede the trade, popular name, or abbreviation of a drug the first time it occurs.

Footnotes. Title page footnotes should be numbered consecutively. Text footnotes should not be used, the material should be incorporated into the text. Table footnotes: see *Tables* (b).

References. Literature cited should be numbered in brackets in text (only one reference to a number) and listed in alphabetical order on a separate sheet at the end of the manuscript. *Do not recite names of authors within the text.* Journal citations in the reference list should contain the following: (a) surnames and initials of all authors (surname of first author precedes initials; initials precede surnames of all co-authors); (b) title of article; (c) journal title abbreviated as listed in the 4th edition of the *World List of Scientific Periodicals*; (d) volume, inclusive pages, and year. Example:

1. Abrams, R. and H. T. Hammel. Hypothalamic temperature in unanesthetized albino rats during feeding and sleeping. *Am. J. Physiol.* 206: 641-646, 1964.

Book references should be in the following order: author, title, city of publication, publisher, year, and

pages. Example:

1. Thompson, T. and C. R. Schuster. *Behavioral Pharmacology*. Englewood, New Jersey: Prentice-Hall, Inc., 1968, p. 297.

Citations such as "Unpublished observations," "Personal communication," "Manuscript in preparation," "To be published," should not be entered in the list of References, but may be noted in the text without serial numbers, in parentheses.

Illustrations. (a) Prepare for use in a single column width whenever possible. (b) All drawings for reduction to a given size should be drawn and lettered to the same scale. (c) All illustrations should be referred to as figures and numbered in Arabic numerals. (d) Lettering should be done in India ink or other suitable material and must be proportionate to the size of the illustrations if it is to be legible after reduction. Lettering should be sized so that its smallest elements (subscripts or superscripts) will be readable when reduced. (e) When possible all lettering should be within the framework of the illustration; likewise the key to symbols should be on the face of the chart. The following standard symbols should be used as they are easily available to the printer. ○ ● △ ▲ □ ■ + (f) Actual magnification of all photomicrographs should be given. Dimension scale should be indicated. (g) Sharply contrasting unmounted photographs of figures on glossy paper are required.

Tables. Due to computer assisted typesetting, choice of format is becoming more limited and the presentation of data in tabular form should be discouraged. In the interest of uniformity, economy and accuracy, wherever possible, tables should be prepared as follows: (a) Tables should be prepared with dry transfer lettering (Prestyle, Normatype, Zipatone, or equivalent) using Futura Demi-bold type style and must be submitted as sharply contrasting unmounted photographs, prepared for single column presentation where possible. Single column - 8.25 cm width; double column - 17.75 cm width. Each table should have a brief typewritten heading (which will be typeset) accompanying it; explanatory matter should be in footnotes, not as part of the title. (b) Table footnotes should be indicated in the body of the table in order of their appearance with the following symbols: † ‡ § ¶ # **, etc. These footnotes should be typewritten (as the heading) to accompany the heading. (c) Tables must not duplicate material in text or illustrations. (d) Vertical rules should be omitted. (e) Short or abbreviated column heads should be used. (f) Statistical measures of variation, SD, SE, etc., should be identified. (g) Analysis of Variance Tables should not be submitted but significant F's should be incorporated where appropriate within the text. The appropriate form for reporting F values is: $F(11,20) = 3.05, p < 0.01$.

Formulas and Equations. Structural chemical formulas, process flow-diagrams, and complicated mathematical expressions should be kept to a minimum. Usually chemical formulas and flow-diagrams should be drawn in India ink for reproduction as line cuts.

All subscripts, superscripts, Greek letters, and unusual characters must be clearly identified.

Anesthesia. In describing surgical procedures on animals, the type and dosage of the anesthetic agent should be specified. Curarizing agents are not anesthetics; if these were used, evidence must be provided that anesthesia of suitable grade and duration was employed.

Proofs. Corrections to the proofs must be restricted to printer's errors only. Other than these, any other alterations will be charged to the author.

Reprints. Each author will receive with his galley proofs a reprint order form which must be completed and returned with the proofs. Late orders cannot be filled since reprints are run at the time the Journal is printed. Senior author receives 25 reprints free.

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 5, 1976

SUBJECT INDEX

- Acetoxycycloheximide
 - memory and antibiotics and acetylcholinesterase, 1
- Acetylcholinesterase
 - hippocampal and operant behavior, 371
 - memory and antibiotics, 1
- ACTH 1-39
 - enhancement of muscular function, s179
 - sexual behavior, 539
- ACTH 1-24
 - ³H-lysine brain incorporation, s139
- ACTH 4-9
 - reversal of CO₂ amnesia, s53
- ACTH 4-10
 - analeptic effects, s135
 - memory in elderly humans, s73
 - neuromuscular function, s179
 - sexual behavior, 539
 - short-term memory in humans, s69
- Active avoidance
 - ACTH 4-10-L and -D and memory, s41
 - α-MSH in chicks, s59
- ACTH analogues
 - attention and discrimination, s3
 - infant administration and adult effects, s3
 - passive avoidance, s3
 - sex differences, s3
- ACTH 4-10-D-Phe-7
 - ³H-lysine brain incorporation, s139
 - memory and avoidance learning, s41
- ACTH 4-10-L-Phe-7
 - ³H-lysine brain incorporation, s139
 - memory and avoidance learning, s41
- Activity
 - d-amphetamine and apomorphine, 627
 - d-amphetamine and novel stimulus, 687
 - brain 5-HT and hypertension, 559
 - bulbectomy and amphetamine, 189
 - butanediols and liver NAD activity, 263
 - d and l-amphetamine and tolerance, 645
 - diethylthiocarbamate and FLA-63 and triiodothyronine, 87
 - 5-HT and NE depletion and d-amphetamine and fenfluramine, 519
 - intracisternal administration of γ-aminobutyric and glutamic acid, 11
 - LH brain stimulation and tryptophan and 5-HT, 241
 - lithium cortical and plasma levels, 379
 - magnesium deficiency and audiogenic seizures, 529
 - methadone, 367
 - MFB and 6-OHDA, 565
 - MSG, 551
 - NA synthesis from l-dopa, 431
 - PCPA and α-methyltyrosine and tranylcypromine and lithium, 515
 - progesterone and infant behavior and development, 587
 - thyroxine and scopolamine, 449
 - typtolines, 383
- Adjunctive behavior
 - drinking and ripazepam and diazepam, 139
 - schedule induced polydipsia and caffeine, 343
 - schedule induced polydipsia and food deprivation and ethanol elimination rate, 335
 - schedule induced polydipsia and nalaxone and narcotic analgesics, 195
 - theoretical review, 483
- Aggression
 - 5-HT antagonists, 55
 - nicotine and arecoline, 235
 - TRH and d-amphetamine, 665
 - VMH stimulation and PCPA, 391
- γ-Aminobutyric acid (GABA)
 - intracisternal administration and activity, 11
- 6-Aminodopamine
 - self-stimulation and brain catecholamines, 19
- Amnesia
 - CO₂ induction and reversal by ACTH 4-9, s53
- d-Amphetamine
 - activity and temperature and stereotyped behavior, 627
 - activity and tolerance, 645
 - aggression and TRH, 665
 - brain self-stimulation, 149
 - bulbectomy and activity, 189
 - hypothalamic self-stimulation, 505
 - induced head shaking and catecholamines, 29
 - ¹⁴C-leucine uptake and CXM, 571
 - LH brain stimulation and eating, 215
 - maze performance and scopolamine, 293
 - NE and 5-HT depletion and activity and eating, 519
 - novel stimulus, 687
 - operant behavior and chlordiazepoxide and pentobarbital, 285
 - self-administration and methoxamine and pimozide, 477
 - stereotype behavior, 23
 - unit recording and caudate, 349
- l-Amphetamine
 - activity and tolerance, 645
 - hypothalamic self-stimulation, 505
- Analeptic properties
 - ACTH 4-10, LHRH and TRH, s135
- Angiotensin II
 - drinking and LPA, 697
 - drinking in chicken, 5
 - effects on induced drinking, s103
 - LPA and anterior hypothalamus and drinking, 591
- Anterior hypothalamus
 - angiotensin II and carbachol and drinking, 591
 - thermoregulation and NE, 713
- Antibiotics
 - memory and acetylcholinesterase, 1
- Apomorphine
 - activity and temperature and stereotyped behavior, 627
 - d and l-amphetamine and activity and tolerance, 645
 - induced head shaking and catecholamines, 29

- operant behavior and neuroleptic drugs, 671
- sexual behavior and PCPA, 457
- sexual behavior and tolerance, 621
- stereotyped behavior and papaverine, 15
- unit recording and caudate, 349
- Apparatus
 - electrode implantation and recording, 359
 - swivel for infusion, 363
- Arousal
 - TRH in rabbits, s111
- Arecoline
 - aggression, 235
 - substantia nigra lesion and stereotyped behavior, 651
- Arthritis
 - operant behavior and aspirin, 583
- Aspirin
 - arthritis and operant behavior, 583
- Atropine
 - drinking and pilocarpine, 633
 - drug induced catalepsy, 201
 - hippocampal and neocortical EEG, 275
- Attention
 - ACTH 4-10 and memory in elderly humans, s73
 - ACTH 4-10 and short-term memory in humans, s69
 - MIF-I and visual discrimination, s11
 - α -MSH and visual discrimination, s11
 - MSH/ACTH 4-10 and attention in mentally retarded humans, s23
 - MSH/ACTH 4-10 and memory in man, s17
 - MSH/ACTH 4-10 and visual discrimination, s11
 - ventricular ACTH 4-9 and discrimination, s3
- Audiogenic seizure
 - magnesium deficiency and activity, 529
- Avoidance behavior
 - brain 5-HT and hypertension and activity, 559
 - DDC and brain DA, 525
 - DDC and dl-DOPS, 499
 - ethanol and sex differences, 417
 - peptides and discrimination learning, 441
 - raphé stimulation and methysergide, 709
 - scopolamine, 157
 - triethyltin, 299
- Blood-brain barrier
 - uptake of peptides, s151
- Body weight
 - MSG, 551
 - 6-OHDA and LH and zona incerta, 309
 - 6-OHDA hypothalamic and septal lesion in geese, 609
- Bradykinin
 - mesenteric arterial pressure, 219
- Brain
 - anterior hypothalamus, 591, 713
 - brainstem, 617
 - caudate, 149, 349, 465
 - cerebral ventricle, s3, s139
 - cortex, 73, 379
 - dorsal hippocampus, s29
 - frontal cortex, 223
 - hippocampus, 275
 - hypothalamus, 63, 207, 491, 609, 617
 - lateral geniculate, 253
 - lateral hypothalamus (LH), 149, 215, 241, 309
 - lateral preoptic area (LPA), 79, 591, 697, 713
 - lateral ventricle, 63
 - medial forebrain bundle (MFB), 565, 661
 - mesencephalon, 63
 - midbrain reticular formation (MRF), 165
 - neocortex, 275
 - olfactory bulb, 189, 207
 - raphé, 519, 709
 - septum, 609
 - striatum, 63
 - substantia nigra, 107, 651
 - telencephalon, 617
 - thalamus, 423
 - ventromedial hypothalamus (VMH), 391, 609
 - visual cortex, 253
 - zona incerta, 309
- Brain blood flow
 - estradiol and α -MSH, s165
- Brain stimulation
 - hypothalamus and d and l amphetamine, 505
 - LH and d-amphetamine and fenfluramine and phenylpropanolamine and eating, 215
 - LH and tryptophan and 5-HT, 241
 - MFB and β -phenylthylamine, 661
 - plug holder for electrode implantation, 359
 - self and 6-aminodopamine and brain catecholamines, 19
 - self and d-amphetamine and CPZ and clonidine, 149
 - VMH and aggression and PCPA, 391
- Brainstem
 - NE and obesity and food deprivation, 617
- Brattellboro strain
 - vasopressin absence and avoidance learning, s35
- Bulbectomy
 - d-amphetamine and activity, 189
- Butanediols
 - activity and liver NAD activity, 263
- Caffeine
 - operant behavior and schedule induced polydipsia, 343
- Carbachol
 - LPA and anterior hypothalamus and drinking, 591
- Carbon monoxide
 - operant behavior, 257
- Castration
 - PCPA and α -methyl-p-tyrosine and testosterone, 319
- Catalepsy
 - chlorimipramine and fluoxetine and imipramine, 599
 - drug induced and cyproheptadine, 201
 - haloperidol-induced and papaverine, 15
- Catecholamines
 - apomorphine or amphetamine induced head shaking, 29
 - depletion following 6-OHDA and histofluorescence, 207
- Caudate
 - lesion and morphine, 465
 - self-stimulation and d-amphetamine and CPZ and clonidine, 149
 - unit recording and d-amphetamine and apomorphine, 349
- Chlordiazepoxide
 - operant behavior and d-amphetamine and pentobarbital, 285
- Chlorimipramine
 - catalepsy, 599
 - drug induced catalepsy, 201
- p-Chlorophenylalanine (PCPA)
 - activity and α -methyltyrosine and tranylcypromine and lithium, 515
 - operant behavior and LSD and 5-HT, 35
 - MFB self-stimulation and β -phenylthylamine, 661
 - sexual behavior, 319, 329, 457
 - VMH stimulation and aggression, 391
- Chlorpromazine (CPZ)
 - apomorphine or amphetamine induced head shaking, 29
 - brain self-stimulation, 149
- Choline acetyltransferase
 - hippocampal and operant behavior, 371
- CI-628
 - sexual behavior and estradiol, 473
- Clonidine
 - brain self-stimulation, 149
- Cocaine
 - self-administration and environmental differences, 701

- Codeine
 - operant behavior, 577
- Cortex
 - lithium level and activity, 379
 - somatostatin injection and sleep and motor behavior, 73
- Cyclic AMP
 - brain levels and α -MSH and MIF, s117
- Cycloheximide (CXM)
 - ¹⁴C-leucine uptake and sympathomimetic drugs, 571
 - memory and antibiotics and acetylcholinesterase, 1
- Cyproheptadine
 - drug induced catalepsy, 201
- Cytochrome P-450
 - chronic pentobarbital administration, 705
- 2-Deoxy-D-glucose (2-DG)
 - hypothalamus and eating, 491
- Development
 - TRH in infant rats, s65
- Desipramine
 - drug induced catalepsy, 201
- Diazepam
 - adjunctive drinking, 139
 - eating in horses, 495
 - operant behavior, 681
- Diet
 - ethanol and maze performance, 85
 - folic acid restriction and infant behavior, 129
- Diethyldithiocarbamate (DDC)
 - activity and eating and operant behavior, 87
 - avoidance behavior and brain DA, 525
 - avoidance behavior and dl-DOPS, 499
- dl-Dihydroxyphenylserine (dl-DOPS)
 - avoidance behavior and DDC, 499
- 5,6-Dihydroxytryptamine (5,6-DHT)
 - ethanol drinking, 63
- 5,7-Dihydroxytryptamine (5,7-DHT)
 - ethanol drinking, 63
- Dimensional attention
 - MIF-I and visual discrimination, s11
 - α -MSH and visual discrimination, s11
 - MSH/ACTH 4-10 and visual discrimination, s11
- Di-n-propylacetate (DPA)
 - tolerance and motor performance, 511
- Discrimination learning
 - apomorphine and neuroleptic drugs, 671
 - fentanyl and morphine, 401
 - infant ACTH 9-10 and adult effects, s3
 - MIF-I and visual discrimination, s11
 - α -MSH and visual discrimination, s11
 - MSH/ACTH 4-10 and visual discrimination, s11
 - peptides and avoidance behavior, 441
- DOPA potentiation test
 - MIF-I effects, s121
- L-DOPA
 - NA synthesis and activity, 431
- Dopamine (DA)
 - brain and DDC and avoidance behavior, 525
 - brain levels and catalepsy and apomorphine, 15
 - brain levels and ethanol drinking, 63
 - self-stimulation and aminodopamine, 19
- Dopaminergic neurons
 - effects of MIF-I, s125
- Dorsal hippocampus
 - ACTH 4-10 and avoidance behavior, s29
 - Vasopressin and avoidance behavior, s29
- Drinking
 - adjunctive and diazepam and ripazepam, 139
 - angiotensin II and carbachol and LPA and anterior hypothalamus, 591
 - angiotensin II in chicken, 5
 - effects of angiotensin II, s103
 - LPA and angiotensin II, 697
 - 6-OHDA and LH and zona incerta, 309
 - pilocarpine, 633
 - scopolamine, 157
 - tetraethyl lead, 387
- Drug
 - acetoxycycloheximide, 1
 - ACTH 1-24, s139
 - ACTH 1-39, s179, 539
 - ACTH 4-9 (Organon 2766), s3, s53
 - ACTH 4-10, s69, s73, s135, s139, s179, 539
 - ACTH 4-10-D-Phe-7, s41, s139
 - ACTH 4-10-L-Phe-7, s41, s139
 - γ -aminobutyric acid (GABA), 11
 - d-amphetamine, 23, 29, 149, 189, 215, 285, 293, 349, 477, 505, 519, 571, 627, 645, 665, 687
 - l-amphetamine, 505, 645
 - angiotensin II, 5, s103, 591, 697
 - apomorphine, 15, 29, 349, 457, 621, 627, 645, 671
 - arecoline, 235, 651
 - aspirin, 583
 - atropine, 201, 275, 633
 - azaperone, 671
 - benperidol, 671
 - bradykinin, 219
 - butanediol, 263
 - caffeine, 343
 - carbachol, 591
 - carbon monoxide, 257
 - chlordiazepoxide, 285
 - chlorimipramine, 201, 599
 - chlorpromazine (CPZ), 29, 149, 175, 671
 - CI-628, 473
 - cinanserine, 55
 - clonidine, 149
 - clozapine, 175
 - cocaine, 701
 - codeine, 577
 - cycloheximide, 1, 571
 - cyproheptadine, 55, 201
 - desipramine, 201
 - 2-DG, 491
 - diazepam, 139, 175, 495, 681
 - diethyldithiocarbamate (DDC), 87, 499, 525
 - dl-dihydroxyphenylserine (dl-DOPS), 499
 - 5,6-dihydroxytryptamine (5,6-DHT), 63
 - 5,7-dihydroxytryptamine (5,7-DHT), 63
 - di-n-propylacetate (DPA), 511
 - DOPA, s121
 - l-DOPA, 431
 - droperidol, 671
 - enkephalin, 691
 - eserine, 275
 - estradiol, s165, 329, 539
 - ethanol, 63, 85, 227, 275, 335, 409, 417, 577
 - ether, 111
 - etonitazene, 195
 - fenfluramine, 215, 519
 - fentanyl, 401
 - FLA-63, 87, 117, 431
 - fluoxetine, 599
 - fluphenazine, 201
 - glutamic acid, 11
 - glycerine trinitrate, 219
 - haloperidol, 15, 29, 175, 671
 - 6-hydroxydopamine (6-OHDA), 63, 107, 207, 309, 565, 609
 - 5-hydroxytryptamine (5-HT), 241
 - imipramine, 201, 599
 - insulin, 491
 - isoprenaline, 571
 - isoproterenol, 219

- ¹⁴C-leucine, 571
 LHRH, s89, s135, s171
 lithium, 143, 379, 515, 547
 β-LPH, s159
 LSD, 35, 223, 621
³H-lysine, 111
 meperidine, 195
 methadone, 175, 195, 367
 methamphetamine, 175
 methiothepin, 55
 methoxamine, 477, 571
 methylmercury, 253
 α-methyl-p-tyrosine, 319, 431, 661
 α-methyltyrosine, 201, 515, 651
 methysergide, 55, 709
 metrazol, 423
 mianserin, 55
 MIF, s11, s79, s89, s117, s125, s151
 monosodium glutamate (MSG), 551
 MOPEG-SO₄, 431
 morphine, 95, 195, 395, 401, 465, 603, 701
 α-MSH, s11, s59, s117, s151, s159, s165, s179, 219
 β-MSH, s159, s179
 MSH/ACTH 4-10, s11, s17, s23, s29, s159
 nalaxone, 195, 465, 603
 nialamide, 241
 nicotine, 235
 nomifensine, 201
 norepinephrine (NE), 571, 713
³H-NE, 491
 papaverine, 15
 PCPA, 35, 55, 319, 329, 391, 457, 661
 pentobarbital, 285, 535, 681, 705
 phencyclidine, 651
 phenobarbital, 175
 phenoxybenzamine, 29, 135
 phentolamine, 175
 phenylalanine ammonia-lyase, 47
 phenylpropanolamine, 215
 β-phenylthylamine, 661
 physostigmine, 175
 pilocarpine, 201, 633
 pimozide, 201, 477, 651, 671
 piperoxane, 571
 pizotyline, 55
 prostaglandin E₁, 219
 prostaglandin E₂, 219
 progesterone, 495, 587
 promazine, 495
 promethazine, 201
 propranolol, 29, 135
 puromycin, 1, 117
 puromycin aminonucleoside, 1
 Ro 4-4602, 241
 reserpine, 201, 431
 ribazepam, 139
 scopolamine, 39, 55, 157, 275, 293, 449, 633
 sodium azide, 299
 somatostatin, 73
 spiperone, 201, 671
 spiroperidol, 175
 SRIF, s171
 tetraethyl lead, 387
 Δ9-tetrahydrocannabinol (Δ9-THC), 79, 123, 269, 409, 639
 thyrotropine-releasing hormone (TRH), 665
 thyroxine, 449
 tranycypromine, 515
 TRH, s65, s79, s89, s95, s111, s129, s135, s171
 triethyltin, 299
 trifluoperidol, 671
 trihexyphenidyl, 651
 triiodothyronine, 87
 tryptolines, 383
 tryptophan, 241
 U14624, 117
 vasopressin, s29, s151
 xylamide, 55
- Eating**
 bullectomy and amphetamine, 189
 diazepam and promazine, 495
 diethylthiocarbamate and FLA-63 and triiodothyronine, 87
 5-HT and NE depletion and d-amphetamine and fenfluramine, 519
 hypothalamus and 2-DG, and glucose and insulin, 491
 LH brain stimulation and d-amphetamine and fenfluramine and phenylpropanolamine and eating, 215
 6-OHDA and LH and zona incerta, 309
 6-OHDA hypothalamic and septal lesion in geese, 609
 scopolamine, 157
 tetraethyl lead, 387
- EEG**
 ACTH 4-10 and attention in man, s17
 hippocampal and neocortical and atropine and scopolamine, 275
 morphine, 95
 sleep and phenoxybenzamine and propranolol, 135
 sleep cycles and MRF protein perfusate analysis, 165
 triethyltin, 299
 visual stimulation and metrazol, 423
- Emotional behavior**
 LHRH, MIF and TRH in humans, s89
 TRH in depressed human patients, s95
- Emotionality**
 TRH in infant rats, s65
- Enkephalin**
 maze performance, 691
- Environmental differences**
 morphine and cocaine self-administration, 701
- Eserine**
 hippocampal and neocortical EEG and atropine and scopolamine, 275
- Estradiol**
 blood flow in rat brain, s165
 sexual behavior and ACTH 4-10, 593
 sexual behavior and CI-628, 473
 sexual behavior and PCPA, 329, 473
- Ethanol**
 Δ-9-THC and motor performance and tolerance, 409
 avoidance and sex differences, 417
 diet and maze performance, 85
 drinking and 6-OHDA and 5,6-DHT and 5,7-DHT, 63
 elimination rate and food deprivation and schedule induced polydipsia, 335
 hippocampal and neocortical EEG and atropine and scopolamine, 275
 operant behavior, 227, 577
- Ether**
³H-lysine uptake by brain and liver protein, 111
- Etonitazene**
 schedule induced polydipsia and nalaxone, 195
- Evoked responses**
 methyl mercury and visual cortex and lateral geniculate, 253
- Fenfluramine**
 LH brain stimulation and eating, 215
 NE and 5-HT depletion and activity and eating, 519
- Fentanyl**
 discrimination learning, 401
- FLA-63**
 activity and eating and operant behavior, 87
 maze learning, 117

- NA synthesis from l-dopa and activity, 431
- Fluoxetine
catalepsy, 599
- Fluphenazine
catalepsy and cyproheptadine, 201
- Folic acid
dietary restriction and infant behavior, 129
- Food deprivation
brain NE and obesity, 617
ethanol elimination rate and schedule induced polydipsia, 335
- Freezing response
scopolamine, 157
- Frontal cortex
lesion and LSD and visual discrimination, 223
- Glucose
hypothalamus and eating, 491
- Glutamic acid
intracisternal administration and activity, 11
- Glycerine trinitrate
mesenteric arterial pressure, 219
- Haloperidol
apomorphine or amphetamine induced head shaking, 29
induced-catalepsy and papaverine, 15
- Handling
³H-lysine uptake by brain and liver protein, 111
- Head-shaking
d-amphetamine, 23
apomorphine or amphetamine induced and catecholamines, 29
- Hippocampus
choline acetyltransferase and acetylcholinesterase and operant behavior, 371
EEG and atropine and scopolamine, 275
- Histofluorescence
6-OHDA and catecholamine depletion, 207
- Hormones
ACTH 1-39, s179
ACTH 4-10, s69, s73, s135, s179, s539
estradiol, 329, 473, 539
 α -MSH, 241
progesterone, 539, 587
testosterone, 319, 457
thyrotropin-releasing hormone, 665
- 6-Hydroxydopamine (6-OHDA)
catecholamine depletion and histofluorescence, 207
ethanol drinking, 63
hypothalamic and septal lesion in geese and body weight and eating, 609
LH and zona incerta and eating and drinking and body weight and temperature, 309
MFB and activity, 565
substantia nigra lesion and stereotyped behavior, 107
- 5-Hydroxytryptamine (5-HT)
antagonists and aggression, 55
brain level and activity and hypertension and avoidance behavior, 559
brain level and ethanol drinking, 63
brain level and methadone, 367
depletion and d-amphetamine and fenfluramine, 519
LH brain stimulation and activity, 241
operant behavior and PCPA and LSD, 35
- Hypertension
brain 5-HT and activity, 559
- Hyperthermia
TRH in rabbits, s111
- Hypothalamus
brain stimulation and d and l amphetamine, 505
DA and 5-HT and NE levels and ethanol drinking, 63
2-DG and glucose and insulin and eating, 491
NE and obesity and food deprivation, 617
- 6-OHDA and catecholamine depletion and histofluorescence, 207
6-OHDA lesion and body weight and eating in geese, 609
- Imipramine
catalepsy, 599
drug induced catalepsy, 201
- Infant behavior
dietary folic acid restriction, 129
progesterone and development and activity, 587
- Insulin
hypothalamus and eating, 491
- Isoprenaline
¹⁴C-leucine uptake and CXM, 571
- Isoproterenol
mesenteric arterial pressure, 219
- Lateral geniculate
evoked responses and methylmercury, 253
- Lateral hypothalamus (LH)
brain stimulation and d-amphetamine and fenfluramine and phenylpropanolamine and eating, 215
brain stimulation and tryptophan and 5-HT, 241
6-OHDA and eating and drinking and body weight and temperature, 309
self stimulation and d-amphetamine and CPZ and clonidine, 149
- Lateral preoptic area (LPA)
angiotensin II and carbachol and drinking, 591
drinking and angiotensin II, 697
lesion and Δ^9 -THC and thermoregulation, 79
thermoregulation and NE, 713
- Lateral ventricle
6-OHDA and 5,6-DHT and 5,7-DHT and ethanol drinking, 63
- Learning
ACTH 4-10-L and -D and long-term memory, s41
TRH and maze learning in rats, s65
vasopressin hereditary lack, s35
- ¹⁴C-leucine
uptake and CXM and sympathomimetic drugs, 571
- β -lipotropic hormone (β -LPH)
effects on motor activity, s159
- Lithium
activity and PCPA and tranycypromine and α -methyltyrosine, 515
cortical and plasma levels and activity, 379
levels in human and monkey brain, 143
sleep, 547
- Liver
³H-lysine uptake and ether and handling, 111
- Long-term memory
ACTH 4-10-L and -D and avoidance tasks, s41
- LSD
frontal cortex lesion and visual discrimination, 223
operant behavior and PCPA and 5-HT, 35
sexual behavior and tolerance, 621
- Luteinizing-hormone-releasing-hormone (LHRH)
analeptic effects, s135
emotional effects in humans, s89
regulatory action on central neurons, s171
- ³H-Lysine
brain and liver uptake and ether and handling, 111
- Magnesium
deficiency and audiogenic seizure and activity, 529
- Maze performance
d-amphetamine and scopolamine, 293
enkephalin, 691
ethanol diet, 85
morphine, 395
puromycin and FLA-63 and U14624, 117
- Medial forebrain bundle (MFB)
6-OHDA and activity, 565
self stimulation and β -phenyl-thylamine, 661

- Memory
 - ACTH 4-9 and amnesia reversal, s53
 - ACTH 4-10 and elderly humans, s73
 - ACTH 4-10 and short-term memory in humans, s69
 - ACTH 4-10-L and -D, s41
 - antibiotics and acetylcholinesterase, 1
 - Δ^9 -THC, 639
- Mental depression
 - TRH effects in humans, s95
- Mentally retarded humans
 - MSH/ACTH 4-10 and improved attention, s23
- Meperidine
 - schedule induced polydipsia and naloxone, 195
- Mesencephalon
 - DA and 5-HT and NE levels and ethanol drinking, 63
- Mesenteric arterial pressure
 - α -MSH, 219
- Methadone
 - activity and 5-HT and NE brain levels, 367
 - pretreatment and methamphetamine and motor activity, 175
 - schedule induced polydipsia and naloxone, 195
- Methamphetamine
 - methadone pretreatment and motor activity, 175
- Methoxamine
 - d-amphetamine self-administration and pimozide, 477
 - ^{14} C-leucine uptake and CXM, 571
- Methyl mercury
 - visual cortex and lateral geniculate evoked responses, 253
- α -Methyl-p-tyrosine
 - MFB self-stimulation and β -phenylthylamine, 661
 - NA synthesis from l-dopa and activity, 431
 - sexual behavior, 319
- N-Methyltransferase inhibitor
 - opiate binding peptide, s147
- α -Methyltyrosine
 - activity and PCPA and tranylcypromine and lithium, 515
 - cataplexy and cyproheptadine, 201
 - substantia nigra lesion and stereotyped behavior, 651
- Methysergide
 - raphé stimulation and avoidance behavior, 709
- Metrazol
 - visual stimulation and EEG, 423
- Midbrain reticular formation (MRF)
 - protein perfusate analysis and sleep cycles, 165
- Monosodium glutamate (MSG), 551
- MOPEG-SO₄
 - NA synthesis from l-dopa and activity, 431
- Morphine
 - caudate lesion, 465
 - discrimination learning, 401
 - EEG and operant behavior, 95
 - maze performance, 395
 - schedule induced polydipsia and naloxone, 195
 - self-administration and environmental differences, 701
 - withdrawal, 603
- Motivation
 - α -MSH and avoidance behavior, s59
- Motor activity
 - β -LPH, s159
 - MIF and TRH in monkeys, s79
 - α -MSH, s 159
 - β -MSH, s159
 - MSH/ACTH 4-10, s159
 - TRH and cyclic AMP in rats, s129
- Motor performance
 - cortical injection of somatostatin, 73
 - DPA and tolerance, 511
 - methadone pretreatment and methamphetamine, 175
 - Δ^9 -THC and ethanol and tolerance, 409
- α -MSH
 - avoidance behavior in chicks, s59
 - blood flow in rat brain, s165
 - cyclic AMP brain levels in rats, s117
 - effects on motor activity, s159
 - mesenteric arterial pressure, 219
 - neuromuscular function, s179
 - sleep and brain respiration in rats, s59
 - visual discrimination and dimensional attention, s11
- β -MSH
 - effects on motor activity, s159
 - neuromuscular function, s179
- MSH/ACTH 4-10
 - attention and memory in man, s17
 - attention in mentally retarded humans, s23
 - dorsal hippocampus and avoidance behavior, s29
 - effects on motor activity, s159
 - visual discrimination and dimensional attention, s11
- MSH-release-inhibitory-factor (MIF)
 - blood-brain barrier, s151
 - cyclic AMP brain levels in rats, s117
 - DOPA potentiation test effects, s121
 - effect on dopaminergic neurons, s125
 - emotional behavior in humans, s89
 - social and motor behavior in monkeys, s79
 - visual discrimination and dimensional attention, s11
- Muscular function
 - ACTH peptide effects, s179
- NAD activity
 - butanediols and activity, 263
- Naloxone
 - caudate lesion and morphine, 465
 - morphine withdrawal, 603
 - schedule induced polydipsia and operant behavior and narcotic analgesics, 195
- Neocortex
 - EEG and atropine and scopolamine, 275
- Nicotine
 - aggression, 235
- Nomifensine
 - drug induced cataplexy, 201
- Noradrenaline (NA)
 - synthesis from l-dopa and activity, 431
- Norepinephrine (NE)
 - brain level and ethanol drinking, 63
 - brain level and methadone, 367
 - brainstem and hypothalamic and telencephalic and obesity and food deprivation, 617
 - depletion and d-amphetamine and fenfluramine, 519
 - ^{14} C-leucine uptake and CXM, 571
 - self-stimulation and 6-aminodopamine, 19
 - thermoregulation and NE, 713
- ^{3} H-Norepinephrine (^{3} H-NE)
 - hypothalamus and 2-DG and glucose and insulin and eating, 49
- Novel stimulus
 - d-amphetamine, 687
- Obesity
 - brain NE and food deprivation, 617
 - MSG, 551
- Olfactory bulb
 - 6-OHDA and catecholamine depletion and histofluorescence, 2
- Operant behavior
 - d-amphetamine and chlordiazepoxide and pentobarbital, 285
 - apomorphine and neuroleptic drugs, 671
 - arthritis and aspirin, 583
 - caffeine and schedule induced polydipsia, 343
 - carbon monoxide, 257
 - codeine and ethanol, 577
 - diazepam and pentobarbital, 681
 - diethylthiocarbamate and FLA-63 and triiodothyronine, 82
 - ethanol, 227
 - hippocampal choline acetyltransferase and acetylcholinesterase, morphine, 95

- PCPA and LSD and 5-HT, 35
 phenylalanine and tyrosine depletion, 47
 schedule induced polydipsia and naloxone and
 narcotic analgesics, 195
 Δ^9 -THC and tolerance, 269
 Δ^9 -THC chronic administration, 123
 Opiate receptor
 opiate binding peptide, s147
- Papaverine
 apomorphine-induced stereotypy and
 haloperidol-induced catalepsy, 15
- Passive avoidance
 ACTH 4-10-L and -D and memory, s41
 infant ACTH 9-10 and adult effects, s3
- Pentobarbital
 chronic and cytochrome P-450, 705
 operant behavior, 681
 operant behavior and d-amphetamine and chlordiazepoxide, 285
 shock, 535
- Peptides
 discrimination learning and avoidance behavior, 441
- Phencyclidine
 substantia nigra and stereotyped behavior, 651
- Phenoxybenzamine
 apomorphine or amphetamine induced head shaking, 29
 sleep EEG, 135
- Phenylalanine
 depletion and operant behavior and sleep, 47
- Phenylpropanolamine
 LH brain stimulation and eating, 215
- β -Phenylthylamine
 MFB self stimulation, 661
- Pilocarpine
 catalepsy and cyproheptadine, 201
 drinking, 633
- Pimozide
 d-amphetamine self administration and methoxamine, 477
 catalepsy and cyproheptadine, 201
 substantia nigra lesion and stereotyped behavior, 651
- Piperoxane
 ^{14} C-leucine uptake and CXM, 571
- Prandial drinking
 effects of angiotensin II, s103
- Progesterone
 infant behavior and development and activity, 587
 sexual behavior and ACTH 4-10, 593
- Promazine
 eating in horses, 495
- Promethazine
 drug induced catalepsy, 201
- Propranolol
 apomorphine or amphetamine induced head shaking, 29
 sleep EEG, 135
- Prostaglandin E_1
 mesenteric arterial pressure, 219
- Prostaglandin E_2
 mesenteric arterial pressure, 219
- Protein
 MRF perfusate analysis and sleep cycles, 165
- Protein synthesis
 ACTH and ^{3} H lysine brain incorporation, 139
- Puromycin
 maze learning, 117
 memory and acetylcholinesterase, 1
- Puromycin aminonucleoside
 memory and antibiotics and acetylcholinesterase, 1
- Raphé
 lesion and 5-HT and NE and d-amphetamine and
 fenfluramine, 519
- stimulation and avoidance behavior, 709
- REM sleep
 MRF protein perfusate analysis, 165
- Reserpine
 catalepsy and cyproheptadine, 201
 NA synthesis from l-dopa and activity, 431
- Ripazepam
 adjunctive drinking, 139
- Salt arousal of drinking
 effects of angiotensin II, s103
- Schedule induced behavior
 theoretical review, 483
- Schedule induced polydipsia
 caffeine and operant behavior, 343
 effects of angiotensin II, s103
 food deprivation and ethanol elimination rate, 335
 naloxone and narcotic analgesics and operant behavior, 195
- Sciatic nerve
 conduction and triethyltin, 299
- Scopolamine
 avoidance behavior and drinking and eating and
 freezing response, 157
 drinking and pilocarpine, 633
 hippocampal and neocortical EEG, 275
 maze performance and d-amphetamine, 293
- Septum
 6-OHDA lesion and body weight and eating in geese, 609
 short-term memory and visual discrimination, 39
 thyroxine and activity, 449
- Sex differences
 avoidance behavior and ethanol, 417
- Sexual behavior
 ACTH 4-10 and ACTH 1-39, 539
 apomorphine and LSD and tolerance, 621
 estradiol and CI-628, 473
 PCPA, 457
 PCPA and estradiol, 329
 PCPA and α -methyl-p-tyrosine and testosterone, 319
- Shock
 pentobarbital, 535
- Short term memory
 scopolamine, 39
- Sleep
 cortical injection of somatostatin, 73
 EEG and phenoxybenzamine and propranolol, 135
 lithium, 547
 MRF protein perfusate analysis, 165
 α -MSH and rats, s59
 phenylalanine and tyrosine depletion, 47
- Social behavior
 LHRH, MIF and TRH in humans, s89
 MIF and TRH in monkeys, s79
- Sodium azide
 triethyltin and avoidance behavior and EEG and
 sciatic nerve conduction, 299
- Somatostatin, growth hormone release inhibiting hormone (SRIF)
 cortical injection and motor behavior and sleep, 73
 regulatory action on central neurons, s171
- Spiperone
 catalepsy and cyproheptadine, 201
- Stereotyped behavior
 d-amphetamine and apomorphine, 627
 d-amphetamine and headshaking, 23
 d-amphetamine and novel stimulus, 687
 apomorphine-induced and papaverine, 15
 apomorphine and amphetamine induced head shaking and
 catecholamines, 29
 bulbectomy and amphetamine, 189
 cortical injection of somatostatin, 73
 6-OHDA lesion of the substantia nigra, 107
 substantia nigra lesion and phencyclidine, 651

- Striatum
 - DA and 5-HT and NE levels and ethanol drinking, 63
- Substantia nigra
 - lesion and phencyclidine and stereotyped behavior, 651
 - 6-OHDA lesion and stereotyped behavior, 107
- Tachypnea
 - TRH in rabbits, s111
- Telencephalon
 - NE and obesity and food deprivation, 617
- Temperature regulation
 - d-amphetamine and apomorphine, 627
 - 6-OHDA and LH and zona incerta, 309
- Testosterone
 - sexual behavior and PCPA, 457
 - Sexual behavior and PCPA and α -methy-p-tyrosine, 319
- Tetraethyl lead
 - eating and drinking, 387
- Δ^9 -Tetrahydrocannabinol (Δ^9 -THC)
 - and ethanol and motor performance and tolerance, 409
 - chronic administration and operant behavior, 123
 - LPA lesion and thermoregulation, 79
 - memory, 639
 - operant behavior and tolerance, 269
- Thalamus
 - knife-cuts and visual stimulation and metrazol and EEG, 423
- Thermoregulation
 - LPA and anterior hypothalamus and NE, 713
 - LPA lesion and Δ^9 -THC, 79
 - TRH and cyclic AMP, s129
- Thyrotropin-releasing hormone (TRH)
 - aggression, 665
 - analeptic effects, s135
 - cyclic AMP and behavior in rats, s129
 - effects on CNS of rabbits, s111
 - emotional behavior in humans, s89, s95
 - learning, emotionality and development in rats, s65
 - regulatory action on central neurons, s171
 - social and motor behavior in monkeys, s79
- Thyroxine
 - activity and scopolamine, 449
- Tolerance
 - apomorphine and LSD and sexual behavior, 621
 - d and l-amphetamine and activity, 645
 - morphine and maze performance, 409
 - motor performance and DPA, 511
 - Δ^9 -THC and ethanol and motor performance, 409
 - Δ^9 -THC and operant behavior, 269
- Tranycypromine
 - activity and PCPA and α -methyl-tyrosine and lithium, 515
- Triethyltin
 - avoidance behavior and EEG and sciatic nerve conduction, 299
- Trihexyphenidyl
 - substantia nigra lesion and stereotyped behavior, 651
- Triiodothyronine
 - activity and eating and operant behavior, 87
- Tryptolines
 - activity, 383
- Tryptophan
 - LH brain stimulation and activity, 241
- Tyrosine
 - depletion and operant behavior and sleep, 47
- U14624
 - maze learning, 117
- Unit recording
 - d-amphetamine and apomorphine and caudate, 349
- Vasopressin
 - blood brain barrier, s151
 - dorsal hippocampus and avoidance behavior, s29
 - hereditary lack and avoidance behavior, s35
- Vigilance
 - ACTH 4-10 and learning in man, s17
 - α -MSH and avoidance behavior, s59
- Visual cortex
 - evoked responses and methylmercury, 253
- Visual discrimination
 - frontal cortex lesion and LSD, 223
 - MIF-I and dimensional attention, s11
 - α -MSH and dimensional attention, s11
 - MSH/ACTH 4-10 and dimensional attention, s11
 - scopolamine, 39
- Visual stimulation
 - EEG and metrazol, 423
- VMH
 - 6-OHDA lesion and body weight and eating in geese, 609
 - stimulation and aggression and PCPA, 391
- Water deprivation
 - effects of angiotensin II, s103
- Zona incerta
 - 6-OHDA and eating and drinking and temperature, 309

AUTHOR INDEX

- ABELL, C. W., 47
ADAMS, M. D., 559
ADAMS, P. M., 47
ADAMS, R. N., 19
AGRANOFF, B. W., 1
AHLENIUS, S., 319, 329
AMIT, Z., 363
ANISMAN, H., 293
ANKER, R., 587
APPEL, J. B., 35
ARMSTRONG, S., 309, 491
ASSAF, S. Y., 697
AYAD, G., 371
- BABCOCK, D. A., 599
BANERJEE, U., 395
BARBEAU, A., s159
BARCHAS, J. D., 383
BARNETT, A., 55
BARNHART, J. E., 551
BARONE, F. C., 343, s103
BARRANDA, E. G., s35
BARRATT, E. S., 47
BARRETT, J. E., 285, 535
BARTUS, R. T., 39
BEATTIE, M. S., 235
BECKWITH, B. E., s11
BEGLEITER, H., 227
BENNETT, E. L., s41
BELL, R., 687
BENNER, S. C., 633
BERNTSON, G. G., 235
BIDZINSKI, A., 15
BIGELOW, G. E., 681
BIGLER, E. D., 423
BISHOP, P., s59
BISHOP, S. B., 87
BISSETTE, G., s135
BLACKMAN, D. E., 139
BLACKWELL, L. A., 129
BLANK, C. L., 19
BOHUS, B., 539
BOND, N. W., 85
BRAZEAU, P., s171
BRIGHTWELL, D., 639
BROWN, R. F., 495
BROWN, T. S., 417
BROWN, Z. W., 363
BRUSH, F. R., s35
BUCK, D. R., 529
- CALDWELL, D. F., 359
CARDO, B., 371
CAREY, J. C., 87
CAREY, R. J., 223, 519
CARINO, M. A., s111
CARLSON, K. R., 175
CARMAN, J. S., 383
- DEL CARMEN GUIÉRREZ, M., 165
CARNEY, J. M., 577
- CAYER, A., s179
CAZALA, P., 505
CHAMPNEY, T. F., s3
CHAPNICK, B. M., 219
CHRISTENSEN, C. W., s117, s121, s125
CLANCY, J. J., 359
CLARK, C., s73
COHN, M., s129
COHN, M. L., s129
COLPAERT, F. C., 401, 671
CONELY, L., 687
CORNETT, T., 639
COY, D. H., s151, 691
COYLE, I. R., 587
CRAGG, B., 587
CRAIGMILL, A. L., 409
CREEL, D., 705
CROWLEY, T. J., s79
CZECH, D. A., 387
- DAMSTRA, T., 111
DANGUIR, J., 547
DAVENPORT, J. W., 87
DEAN, M. C., s35
DEMENT, W. C., 599
DE NOBLE, V., 227
DESTRADE, C., 371
DE WIED, D., s29
DI GIUSTO, E. L., 85
DOLPHIN, A., 431
DORNBUSH, R. L., s69
DREW, W. G., 639
DRUCKER-COLÍN, R. R., 165
DUNN, A. J., s139
- EBEL, A., 371
EHRENSING, R. H., s89
EIBERGEN, R. D., 175
ELIASSON, M., 621
ELLIOTT, G. R., 383
ELSMORE, T. F., 123
ENGEL, J., 319, 329
ENTINGH, D. J., 111
ERVIN, G. N., 565
EVANS, B. K., 207
- FALK, J. L., 335
FERRIS, S. H., s73
FIBIGER, H. C., 107
FINNEGAN, K. T., 651
FLEMING, D. E., 423
FLEXNER, J. B., 117
FLEXNER, L. B., 117
FLOOD, J. F., s41
FREED, W. J., 11
FRIEDHOFF, A. J., s147
FRIEDMAN, H., 223
FRIESEN, H., 73
FRITZ, R. R., 47
- GADDY, J. R., 189
- GAJEWSKA, S., 15
GALVAN, L., 441
GAY, P. E., 633
GEORGE, J., s23
GERREN, R. A., 299
GERSHON, S., s73
GIBBS, M. E., 571
GIBSON, C. A., s65
GODSCHALK, M., 5
GOLDBORT, R., 263
GOLDMAN, H., s165
GONCE, M., s159
GONZALEZ, E., s179
GREEN, R. A., 383
GREENBERG, R., s151
GRIFFITHS, R. R., 681
GROSWALD, D. E., 299
GROVER, T. A., 129
GROVES, P. M., 349
- HACKETT, J. T., 95
HALL, P. F., 705
HAMBURG, M. D., 499
HARRIS, L. C., s17
HARSTON, C. T., s117, s121
HARTLINE, R. A., 263
HARTMANN, E., 135
HARTO, N. E., 661
HAUPTMAN, M., 15
HAVLICEK, V., 73
HAYCOCK, J. W., 525
HENDRICKS, D. G., 529
HENNIES, R. S., 87
HILL, S. Y., 701
HOEBEL, B. G., 215
HOLMGREN, B., 23, 29
HORITA, A., s111, 627
HOSKO, M. J., 79
HOUP, K. A., 495
HOWARD, J. L., 661
HUGHES, K. R., 73
HYDINGER, M., s79
- IUVONE, P. M., s139
- JAFFARD, R., 371
JANSSEN, P. A. J., 401, 671
JANSSENS-ELBERTSE, R., s53
JARVIK, M. E., s41
JEFFREY, P. L., 571
JENNER, P., 431
JOH, T. H., s125
JOHNSON, H. R., 39
JOLICOEUR, F. B., 343, s103
JONES, B. E., 477
JOSEPH, J. A., 35
JOURDIKIAN, F., s151
- KADOWITZ, P. J., 219
KANNER, M. I., 651

- KASTIN, A. J., s11, s17, s23, s59, s65, s89, s117, s121, s125, s151, s159, s165, 219, 691
- KATZ, R. J., 391
- KERR, A., 499
- KING, M. G., 691
- KLARA, J. W., s125
- KLIMEK, V., 201
- KOKKINIDIS, L., 293
- KOLAR, K. G., s65
- KOMISARUK, B. R., 457
- KORNBLITH, C. L., 215
- KOSTOWSKI, W., 15
- KOSTRZEWA, R. M., s117, s121, s125
- KOVÁCS, G. L., 709
- KRZYSIK, B. A., s129
- KUFNER, M., 687
- KULIG, B. M., 511
- KUYPS, J. J. M. D., 401
- LAL, H., 395
- LANDAU, I. T., 473
- LAPIN, I. P., 241, 247
- LARA, P. P., s95
- LARSSON, K., 319, 329
- LAUDENSLAGER, M. L., 713
- LEAF, R. C., 633
- LEANDER, J. D., 195
- LEYSEN, J. E. M. F., 671
- LIEBSON, I. A., 681
- LINSEMAN, M. A., 465
- LIPTON, M. A., s135
- LLEWELLYN, M. E., 577
- LOOSEN, P. T., s95, s135
- LORDEN, J. F., 617
- LUTTGES, M. W., 299
- MCFARLAND, D., 639
- MCGAUGH, J. L., 525
- MCINTIRE, R. W., 257
- MCMILLAN, D. E., 195
- MCQUEEN, A., 491
- MAHONEY, A. W., 529
- MAJ, J., 201
- MALICK, J. B., 55, 665
- MANDEL, P., 371
- MANNING, F. J., 269
- MARCZYNSKI, T. J., 95
- MARGULES, D. L., 617
- MARSDEN, C. D., 431
- MARTIN, J. B., s171
- MARZULLO, G., s147
- MEEKER, R. B., s59
- MELCHIOR, C. L., 63
- MELTZER, H. Y., 651
- MENDELSON, I. S., s151
- MERIGAN, W. H., 257
- MERKEL, A. D., s103
- MEYER, D. R., 603
- MEYERSON, B. J., 539
- MICHAELIS, E. K., 11
- MIDDAUGH, L. D., 129, 367
- MILLER, L., 639
- MILLER, L. H., s17
- MILLER, M., s35
- MITLER, M. M., 599
- MOGENSON, G. J., 697
- MOLLENAUER, S., 157
- MONASMITH, B., 19
- MORGAN, D. C., 335
- MOSHINSKY, J., s73
- MURPHY, J. M., 449
- MURPHY, S., s165
- MYERS, R. D., 63, 491
- NAGGAR, A. N., 457
- NAGY, Z. M., 449
- NARVER, E. L., 599
- NEILL, D. B., 189
- NEMEROFF, C. B., s135
- NICOLAIDIS, S., 547
- NIEMEGERES, C. J. E., 401, 671
- NIKOLICS, K., s151
- NIKOLOVSKI, O., s69
- NOLAN, J. D., s23
- NUMAN, R., 395
- OLTMANS, G. A., 617
- ORME, A. E., s41
- OVERSTREET, D. H., 645
- PALET, J., 687
- PANKSEPP, J., s59
- PATKINA, N. A., 241, 247
- PECK, J. W., 591
- PEREK, M., 609
- PERINO-MARTEL, M.-C., 547
- PIZZI, W. J., 551
- PLOTNIK, R., 157
- PLOTNIKOFF, N. P., s121
- PLOTSKY, P., 19
- POFFENBARGER, P. L., 47
- POLLARD, G. T., 661
- POWELL, B. J., 701
- PRANGE, A. J., JR., s95, s135
- PRICE, C. M., 335
- PRICE, M. T. C., 107
- QUOCK, R. M., 627
- RAVONA, H., 609
- RAWŁÓW, A., 201
- REBEC, G. V., 349
- REES, H. D., s139
- REILLY, P., s59
- RENAUD, L. P., s171
- REVZIN, A., 149
- REZEK, M., 73
- RIGTER, H., s53
- RISNER, M. E., 477
- ROBINSON, T. E., 275
- ROBINZON, B., 5, 609
- RODRIGUEZ-SIERRA, J. F., 457
- ROHRBACH, K. W., 661
- RONDEAU, D. B., 343, s103
- ROSECRANS, J. A., 559
- ROSENGARTEN, H., s147
- SAHLEY, T. L., s3
- SAMSON, H. H., 335
- SANDMAN, C. A., s3, s11, s23, s165
- SANGER, D. J., 139
- SARNEK, J., 201
- SATHANANTHAN, G., s73
- SCHACHT, J., 1
- SCHALLERT, T., 275
- SCHALLY, A. V., s151, 691
- SCHMELLING, W. T., 79
- SCHMIDT, J. C., 387
- SCHNEIDER, C. W., 263
- SCHREIBER, H., 687
- SCHRYVER, H. F., 495
- SCOLLAN, E. L., 691
- SHEARER, D. E., 423, 705
- SHIMIZU, M., 515
- SINGER, G., 207, 309, 483, 491
- SKELLEY, E. B., s165
- SMITH, D. F., 379, 515
- SMITH, G. P., s65
- SMITH, J. R., s111
- SMITH, M. D., 257
- SMITH, N., 395
- SNAPIR, N., 5, 609
- SÖDERSTEN, P., 319, 329
- SOTZING, J. H., 417
- SOUTHWICK, P., 157
- SPANIS, C. W., 165
- SPARBER, S. B., 603
- SPENCER, J., 149
- SPIRITES, M. A., s117, s121, s125, 143
- SPRAGUE, G. L., 409
- SPRINGER, A. D., 1
- STOBOY, H., s179
- STONE, J. M., 387
- STRAND, F. L., s179
- STRATTON, L. O., s65
- SZOPO, J. M., 359
- TANG, M., 335
- TATE, D. F., 441
- TAYLOR, F. H., s129
- TELEGDY, G., 709
- THOMAS, E., 391
- UNGAR, G., 441
- URBÁ-HOLMGREN, R., 23, 29
- VALDÉS, M., 23, 29
- VAN BUSKIRK, R., 525
- VAN RIEZEN, H., s17, s53
- VILBERG, T. R., s59
- WALKER, B., s23
- WALKER, J. M., 235
- WALLACE, M., 483
- WALTER, R., s151
- WAYNER, M. J., s103, 343
- WEEKS, J. R., 363
- WEISSMAN, A., 583
- WESTON, P. F., 645
- WHALLEY, C. E., s151
- WHISHAW, I. Q., 275
- WIKLER, A., 639
- WILLIS, G. L., 207
- WILSON, I. C., s95
- WIMERSMA GREIDANUS, T. J. B. VAN, s29
- WITKIN, J. M., 285, 535
- WOODS, J. H., s77
- WRIGHT, L., 687
- WYATT, R. J., 383
- YAAKOBI, M., 609
- YOUNG, R. C., s65
- ZEMP, J. W., 129, 367
- ZWILLING, G., 135
- ZENICK, H., 253

